Conclusions
-
1)
The statistical methods utilized by UGDP investigators were inappropriate to the biopharmacological nature of the questions addressed and the conclusions drawn from the study.
-
2)
The anomalous sex ratio of cardiovascular deaths in PLBO subjects constitutes a spurious result which renders suspect all UGDP conclusions based on comparison with that group.
Again, one must ask, “How and why did these problems happen and how can they be avoided in the future?” Our findings indicate the answer to the second part of the question; only UGDP investigators themselves can answer the first.
Article PDF
Avoid common mistakes on your manuscript.
References
University Group Diabetes Program (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: Sections I and II. Diabetes 19 (Suppl 2): 747–830
University Group Diabetes Program (1974) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: Section V. Evaluation of phenformin therapy. Diabetes 24 (Suppl 1): 65–184
Knatterud G, Klimt CR, Levin ME, Jakobsen ME, Goldner MG (1978) Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: Section VII. Mortality and selected nonfatal events with insulin treatment. JAMA 240:37–42
Feinstein AR (1971) Commentary. Clinical biostatics — VIII. An analytic appraisal of the University Group Diabetes Program (UGDP) Study. Clin Pharmacol Ther 12:167–191
Schor SS (1971) The University Group Diabetes Program. A statistician looks at the mortality results. JAMA 217:1671–1675
Seltzer HS (1972) A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21:976–979
O'Sullivan JB (1973) Discussion. In: Camerini-Davalos RA, Cole HS (eds) Vascular and neurological changes in early diabetes. Academic Press, New York, p 509–512
Schor SS (1973) Discussion. In: Camerini-Davalos RA, Cole HS (eds) Vascular and neurological changes in early diabetes. Academic Press, New York, p 512–516
Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents (1975) Report. JAMA 231:583–608
Moss JM (1975) Letter to the Editor. JAMA 232:806–808
Bradley RF, Dolger H, Forsham PH, Seltzer H (1975) Settling the UGDP controversy? JAMA 232:813–817
O'Sullivan JB, D'Agostino RB (1975) Decisive factors in the tolbutamide controversy. JAMA 232:825–829
Feinstein AR (1976) Clinical biostatistics — XXXV. The persistent clinical failures and fallacies of the UGDP study. Clin Pharmacol Ther 19:78–93
Feinstein AR (1976) Clinical biostatistics — XXXVI. The persistent biometric problems of the UGDP study. Clin Pharmacol Ther 19:472–485
Feinstein AR (1979) How good is the statistical evidence against oral hypoglycemic agents? Adv Intern Med 24:71–94
Kilo C, Williamson JR, Choi SC, Miller JP (1979) Letter to the Editor: Insulin treatment and diabetic vascular complications. JAMA 241:26–27
Kilo C, Williamson JR, Choi SC, Miller JP (in press) Refuting the UGDP conclusion that insulin treatment does not prevent vascular complications in diabetes. In: Proceedings of the IV International Symposium on Early Diabetes
Kilo C, Miller JP, Williamson JR (in press) The Achilles heel of the University Group Diabetes Program. JAMA
Prout TE, Knatterud GL, Meinen CG (1979) Letter to the Editor. Science 204:362–363
Warren S, LeCompte PM, Legg MA (1966) The pathology of diabetes mellitus. Philadelphia, Lea and Febiger, p 188–199
Bradley RF (1971) Cardiovascular disease. In: Marble A, White P, Bradley R, Krall L (eds) Joslin's diabetes mellitus. Lea and Febiger, Philadelphia, p 417–477
Report of the Workgroup on Mortality (1975) Part 1. Scope and impact of diabetes. In: Report of the National Commission on Diabetes to the Congress of the United States, Vol III. DHEW Publication No (NIH) 76-102. U.S. Government Printing Office, Washington, p 177–247
U.S Department of Health, Education, and Welfare (1977) Diabetes mortality. In: Diabetes data. DHEW Publication No (NIH) 78-1468. U.S. Government Printing Office, Washington, p 59–83
Cornfield J (1971) The University Group Diabetes Program. A further statistical analysis of the mortality findings. JAMA 217:1676–1686
Peterson CM, Jones RL, Koenig RI, Melbin ET, Lehrman ML (1977) Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med 86:425–429
Peterson CM, Koenig RJ, Jones RL, Sander CD, Cerami A (1977) Correlation of serum triglyceride levels and hemoglobin A1c concentrations in diabetes mellitus. Diabetes 26:507–509
Hill AB (1971) In: Principles of medical statistics, Ninth edition. The Lancet Limited, London, p 266
Prout TE (1971) Prospective study of the vascular complications in adult-onset diabetes mellitus: The University Group Diabetes Program. Ann Intern Med 75:607–621
Shen S-W, Bressler R (1977) Clinical pharmacology of oral antidiabetic agents. Part 1. N Engl J Med 296:493–497
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kilo, C., Miller, J.P. & Williamson, J.R. The crux of the UGDP. Diabetologia 18, 179–185 (1980). https://doi.org/10.1007/BF00251913
Issue Date:
DOI: https://doi.org/10.1007/BF00251913